Review
Copyright ©The Author(s) 2020.
World J Stem Cells. Nov 26, 2020; 12(11): 1276-1294
Published online Nov 26, 2020. doi: 10.4252/wjsc.v12.i11.1276
Table 2 Representative clinical trials of mesenchymal stem cell-derived exosomes
Exosome originDiseasesAdministration methodStatusmiRNAs that may be associated with MSC therapy for this disease
Allogenic mesenchymal stromal cellsCerebrovascular disordersIntravenous injectionCompletedMiRNA-184, miRNA-210, miR-133b, miR-17-92[81,82,162]
Allogenic adipose mesenchymal stem cellsCOVID-19Aerosol inhalationPhaseIHas not been reported
Allogenic mesenchymal stromal cellsMultiple organ failureIntravenous injectionNot yet RecruitingHas not been reported
Human UC-MSCsMacular holesIntravitreal injectionPhaseIHas not been reported
Human UC-MSCsDry eyesEye dropsPhase IIHas not been reported
Adipose mesenchymal stem cellAlzheimer’s diseaseNasal dripPhase IIMiR-146a-5p[79]
Human UC-MSCsDiabetes mellitus type 1Intravenous infusionPhase IIIMiR-1908, miR-203a[80]
MSCsCOVID-19InhalationPhase IIHas not been reported
Human UC-MSCsChronic ulcerApplying and closed by transparent dressingCompletedHas not been reported